

学位論文

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of
Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets

(膵島の鉱質コルチコイド受容体は IL-6 および GLP-1 を介して糖代謝を制御する)

後藤 理英子

Rieko Goto

指導教員

荒木 栄一 教授

熊本大学大学院医学教育部博士課程医学専攻代謝内科学

2019年度

学位論文

論文題名 : Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the
Induction of Interleukin-6 and Glucagon-Like Peptide-1 in Pancreatic Islets
(膵島の鉱質コルチコイド受容体は IL-6 および GLP-1 を介して糖代謝を制御する)

著者名 : 熊本大学大学院医学教育部博士課程医学専攻代謝内科学
後藤 理英子

指導教員名 : 熊本大学大学院医学教育部博士課程医学専攻代謝内科学
荒木 栄一 教授

審査委員名 : 病態生化学教授 氏名 山縣 和也
分子生理学教授 氏名 富澤 一仁
分子遺伝学教授 氏名 尾池 雄一
腎臓内科学教授 氏名 向山 政志

2019年度



Article

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets

Rieko Goto ^{1,*} , Tatsuya Kondo ¹, Kaoru Ono ¹, Sayaka Kitano ¹, Nobukazu Miyakawa ¹, Takuro Watanabe ¹, Masaji Sakaguchi ¹, Miki Sato ¹, Motoyuki Igata ¹, Junji Kawashima ¹, Hiroyuki Motoshima ¹, Takeshi Matsumura ¹, Seiya Shimoda ² and Eiichi Araki ^{1,*}

¹ Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan; t-kondo@gpo.kumamoto-u.ac.jp (T.K.); zenmaiing@yahoo.co.jp (K.O.); ramuramusayaka@yahoo.co.jp (S.K.); nomiyakawa@yahoo.co.jp (N.M.); w_takuro_0420@yahoo.co.jp (T.W.); masajisakaguchi@gmail.com (M.S.); satoum@kuh.kumamoto-u.ac.jp (M.S.); iga@gpo.kumamoto-u.ac.jp (M.I.); junjikawa@mac.com (J.K.); hmoto@gpo.kumamoto-u.ac.jp (H.M.); takeshim@gpo.kumamoto-u.ac.jp (T.M.)

² Food and Health Sciences, Prefectural University of Kumamoto, Kumamoto, 862-8502, Japan; sshimoda@pu-kumamoto.ac.jp

* Correspondence: boots0gt@gmail.com (R.G.); earaki@gpo.kumamoto-u.ac.jp (E.A.); Tel.: +81-96-373-5169 (E.A.)

Received: 11 April 2019; Accepted: 9 May 2019; Published: 14 May 2019



Abstract: Because the renin-angiotensin-aldosterone system influences glucose homeostasis, the mineralocorticoid receptor (MR) signal in pancreatic islets may regulate insulin response upon glucose load. Glucagon-like peptide-1 (GLP-1) production is stimulated by interleukin-6 (IL-6) in pancreatic α -cells. To determine how glucose homeostasis is regulated by interactions of MR, IL-6 and GLP-1 in islets, we performed glucose tolerance and histological analysis of islets in primary aldosteronism (PA) model rodents and conducted in vitro experiments using α -cell lines. We measured active GLP-1 concentration in primary aldosteronism (PA) patients before and after the administration of MR antagonist eplerenone. In PA model rodents, aldosterone decreased insulin-secretion and the islet/pancreas area ratio and eplerenone added on aldosterone (E+A) restored those with induction of IL-6 in α -cells. In α -cells treated with E+A, IL-6 and GLP-1 concentrations were increased, and anti-apoptotic signals were enhanced. The E+A-treatment also significantly increased MR and IL-6 mRNA and these upregulations were blunted by MR silencing using small interfering RNA (siRNA). Transcriptional activation of the IL-6 gene promoter by E+A-treatment required an intact MR binding element in the promoter. Active GLP-1 concentration was significantly increased in PA patients after eplerenone treatment. MR signal in α -cells may stimulate IL-6 production and increase GLP-1 secretion, thus protecting pancreatic β -cells and improving glucose homeostasis.

Keywords: Mineralocorticoid receptor (MR); Glucagon-like peptide-1 (GLP-1); interleukin-6 (IL-6); α -cells; glucose homeostasis

1. Introduction

Several large-scale clinical trials have shown that angiotensin II receptor antagonist has significant preventative effects for the onset of diabetes [1]. Results from these trials and other studies have thus demonstrated that the renin angiotensin aldosterone system has an impact on glucose tolerance through modification of insulin resistance and/or insulin secretion [2]. In humans, primary aldosteronism (PA), a leading cause of secondary hypertension, has been associated with diabetes due to impaired insulin

sensitivity and/or insulin secretion [3]. Previous research has suggested that aldosterone decreases glucose-stimulated insulin secretion in vivo and in vitro (in murine islets) [4]. In addition, sub-chronic stimulation of the mineralocorticoid receptor (MR), the receptor for aldosterone, protects pancreatic β -cells against glucocorticoid-induced lower cytosolic Ca^{2+} responses to glucose [5].

A previous report proposed that the administration of interleukin-6 (IL-6) or elevated IL-6 concentrations in response to exercise stimulates incretin hormone glucagon-like peptide 1 (GLP-1) secretion from intestinal L cells and pancreatic α -cells in humans [6]. GLP-1 has been shown to lead to glucose-dependent insulin secretion, induction of β -cell proliferation and enhanced resistance to β -cell apoptosis [7]. Further, a potential role for local IL-6 in the regulation of α -cell growth and function during neonatal development has been demonstrated [8], indicating that local IL-6 may exert beneficial effects on the functional integrity of islets. Indeed, IL-6, IL-6 receptor and glucagon are co-expressed in pancreatic α -cell populations during development in murine islets [8]. Although MR signals may regulate pancreatic islet function, the role of MR in the induction of IL-6 and GLP-1 in islet cells has not been elucidated. The purpose of this study was to clarify the effects of MR signal on pancreatic islets, especially in association with IL-6 and GLP-1.

2. Experimental Section

2.1. Materials Establishment of PA Model Rodents, Treatment Groups and Histological Analysis of Pancreatic Islets

Male Sprague-Dawley rats ($n = 18$), obtained from CLEA Japan Inc. (CLEA Japan Inc., Tokyo, Japan), were housed in the Center for Animal Resources and Development of Kumamoto University. The experimental procedures were approved by the Animal Experimentation Ethics Committee of Kumamoto University (B24-129).

The animals were placed in one of the following 28-day treatment protocols: (1) control (vehicle/normal chow) ($n = 6$); (2) aldosterone infusion (aldosterone/normal chow) ($n = 6$); or (3) aldosterone infusion + oral eplerenone treatment (aldosterone/eplerenone chow) ($n = 6$). We used an Alzet 2004 osmotic mini-pump (Alza Corp., Palo Alto, CA, USA) to administer either vehicle (9% ethanol/87% propylene glycol/4% dH₂O) or 2.9 mg/mL d-aldosterone (Sigma Chemical Company, St. Louis, MO, USA), as previously reported [9]. Eplerenone (provided from Pfizer Inc., New York City, NY, USA) was administered in the chow obtained from Kyudou Ltd. (Saga, Japan) at a concentration of 1.2 mg eplerenone/g of chow, resulting in an approximate dose of 100 mg/kg/day, according to the previous report [9]. During the experiments, all rats drank 1% saline (wt/vol.) for 4 weeks prior to the study.

On day 28, plasma aldosterone concentration (PAC), blood pressure, body weight and serum potassium level of each treatment group were measured. Glucose tolerance was examined in each treatment group using the 2 g/kg intraperitoneal glucose tolerance test (ipGTT) on day 28.

After the treatments, animals were anesthetized with 50 mg/kg pentobarbital and 30% isoflurane diluted with propylene glycol (Wako, Japan) and exsanguinated. The pancreas from each rat was isolated and routinely processed and embedded in paraffin or immediately snap-frozen in liquid nitrogen. Pancreas sections (3 μm) from paraffin blocks were dyed with Masson's trichrome staining. Other pancreas sections (5 μm) from frozen blocks were immunostained following standard procedures using primary antibodies for IL-6 (No. 18611, Immuno-Biological Laboratories Co., Ltd., Gunma, Japan), glucagon (sc-13091, SANTA CRUZ BIOTECHNOLOGY, Dallas, TX, USA), MCP-1 (No. 18371, Immuno-Biological Laboratories Co.), Iba1 (Wako, Japan) and CD206 (sc-9139, SANTA CRUZ BIOTECHNOLOGY). The size of each pancreatic islet area was measured and compared using BZ-9000 (Keyence Corp., BIOREVO, Chicago, IL, USA).

2.2. Cell Lines and Treatments

The 1C3 IKEI pancreatic cell line was kindly provided by H. Ishikawa (Nippon Dental University entrusted to RIKEN BRC, Japan). Alpha TC1 clone 6 cells (α TC cells) (ATCC, Manassas, VA, USA) and the 1C3 IKEI cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 25 mmol/L glucose with 10% steroid-free FBS (Sigma Aldrich, St. Louis, MO, USA) and antibiotics (100 μ g/mL streptomycin, 100 units/mL penicillin, 0.25 μ g/mL amphotericin B), in the presence or absence of 10^{-7} M aldosterone, 10^{-5} M eplerenone or a combination of the two treatments [10]. Cells were cultured at 37 °C in a humidified atmosphere with 5% CO₂.

2.3. Glucose Homeostasis of PA Patients before and after Treatment

This study is a prospective study and enrolled 13 patients who were diagnosed with PA at the Kumamoto University hospital between 2014 and 2017. In accordance with the diagnosis of PA described by the Japan Endocrine Society, the diagnosis was performed using the result of plasma aldosterone concentration (pg/mL) / plasma renin activity (ng/mL/hr) ratio (ARR > 200), the captopril suppression test (ARR > 200 at 60 min after loading 50mg of captopril) and the adrenal vein sampling. Glucose tolerance was examined in the 13 patients using the 75 g oral glucose tolerance test (75 g OGTT) before and after the treatments of PA (one to three months after eplerenone administration (50 mg average per day)). We used the 2006 WHO recommendations for the diagnostic criteria for normal glucose tolerance (fasting plasma glucose (FPG) < 110 mg/dL and 2 hour plasma glucose (2-h PG) < 140 mg/dL), impaired glucose tolerance (FPG 110–125 mg/dL and 2-h PG 140–199 mg/dL) and diabetes mellitus (FPG > 126 mg/dL or 2-h PG > 200 mg/dL). Active GLP-1 concentration was determined 60 min after the glucose load.

The study protocol was confirmed by the ethical guidelines of the Declaration of Helsinki and written informed consent was obtained from each patient. This research was approved by the Ethics Review Committee at Kumamoto University (Advanced Ethics No. 1956). Clinical trials were registered with an approved International Committee of Medical Journal Editors (ICMJE) clinical trial registry, University Hospital Medical Information Network (UMIN) clinical trials registry (ID: UMIN000017666).

2.4. ELISA Assays

Insulin, IL-6 or active GLP-1 concentrations were assayed with commercial ELISA kits according to the manufacturer's instructions (LBIS Insulin-Rat-T, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan; hIL-6 QKit, R&DSYSTEMS, Minneapolis, MN, USA; IL-6 ELISA kit, Mouse, Proteintech Group, Inc., Rosemont, IL, USA; GLP-1, Active Form Assay Kit, Immuno-Biological Laboratories Co., Ltd., Fujioka-Shi, Gunma, Japan).

2.5. RT-PCR

cDNA was synthesized from total RNA prepared from cells using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). Expression levels of genes were determined by reverse transcription PCR (RT-PCR) using the ReverTra Ace@qPCR RT Master Mix (TOYOBO, Kita-ku, Osaka, Japan) and Fast-Start DNA Master Plus SYBER Green (Roche Diagnostics, Basel, Switzerland) on a LightCycler 2.0 (Roche Diagnostics). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as a normalization control for RNA quality, RNA quantity and RT method. Primer sequences are shown in Table S1.

2.6. siRNA Transfection

On the day before transfection, α TC1 cells were seeded in 6-well plates and cultured overnight until cells reached 75% confluence. Cells were transiently transfected with siRNA (100 pmol/well, Stealth siRNA, Santa Cruz) using Lipofectamine 2000 (5 μ L/well, Invitrogen, Paris, France) mixed with OptiMEM serum-free medium (Invitrogen, Paris, France). Four hours after transfection, cells were

washed twice with phosphate buffered saline (PBS) and then cultured in the presence or absence of a combination of the aldosterone and eplerenone treatments. The siRNA sense sequence (siMR, siGR) and the control sense sequence (CONMR, CONGR) for MR and GR are shown in Table S2.

2.7. Reporter Plasmids Construction and Luciferase Assay

The human MR expression vector (pRR-MR-5Z) and the human GR expression vector (pk7-GR-GFP) were obtained from Charles Miller (No. 23059, No. 15534, Addgene, Cambridge, MA, USA) [11,12].

The IL-6 promoter region was amplified by PCR from human genomic DNA (QuickGene, Kurabo) for the construction of the IL-6 Luc plasmid. The IL-6 Mutant Luc plasmid, containing mutations in the MR binding element (MRE), was constructed by inserting pairs of complementary hybridized oligonucleotides. The list of qPCR primers for IL-6 promoter and sense sequence for mutated MRE are shown in Table S3. The IL-6 promoter sequences were then ligated into the PGL-3 vector after digestion with KpnI and XhoI to generate luciferase reporter vectors. Luciferase assay was performed using the Dual-Luciferase® Reporter Assay System (Promega) according to the manufacturer's instructions.

2.8. Statistical Analysis

Statistical analysis was performed with SPSS software (IBM, Chicago, IL, USA). All values were expressed as mean \pm standard deviation (S.D.). Data were evaluated using Chi-square tests or paired t-tests if data were normally distributed or a Wilcoxon signed-rank test if not. Sequential changes were analyzed by repeated-measures ANOVA. Two-sided *p*-values of less than 0.05 were considered to indicate statistical significance.

3. Results

3.1. Eplerenone Treatment Protects Islet Cells from Cell Damage Caused by Aldosterone

To examine the effects of MR signals in pancreatic islets, we generated a rodent PA model by aldosterone infusion and examined the impact of eplerenone treatment. Sprague Dawley rats were randomly placed in one of the following 28-day treatment groups: vehicle (Control), aldosterone infusion (2.9 mg/mL) (Aldosterone) or aldosterone infusion (2.9 mg/mL) with eplerenone administration (100 mg/day/kg) (E+A).

Plasma aldosterone concentration was significantly increased in the Aldosterone group compared with the Control group or E+A group (Figure 1A). Systolic and diastolic blood pressure values were significantly increased in the Aldosterone group compared with the Control group or E+A group (Figure 1B). There was no significant difference in body weight (Figure 1C). Serum potassium level was significantly lower in the Aldosterone group than that in the Control group or the E+A group (Figure 1D).

Blood glucose was higher in the Aldosterone group than that in the Control group or the E+A group (Figure 1E). Area under the curve (AUC) of blood glucose concentration during ipGTT was significantly increased in the Aldosterone group compared with the Control group or the E+A group (Figure 1F). IRI was lower in the Aldosterone group than that in the Control group or the E+A group (Figure 1G). AUC of IRI during ipGTT was significantly decreased in the Aldosterone group compared with the Control group (Figure 1H).

Histological analysis revealed that the islet/pancreas area ratio was significantly reduced in the Aldosterone group compared with the Control group and was completely restored in the E+A group (Figure 2A–C,G).

The percentage of the α -cell area was significantly increased in the Aldosterone group compared with the Control group or E+A group (% α -cell area in islet area: 24.6% \pm 5.9% vs. 45.5% \pm 5.1% vs. 17.3% \pm 3.0% in Control, Aldosterone and E+A groups, respectively; *p* < 0.05) (Figure 2D–F,H).




Figure 1. Comparisons of each parameter in primary aldosteronism (PA) model rodents on day 28. Rats were randomized into three treatment groups ($n = 6$ each group): control, treated with vehicle; aldosterone, treated with 2.9 mg/mL d-aldosterone; and E+A, treated with d-aldosterone and 100 mg/kg/day oral eplerenone administration. (A) Plasma aldosterone concentration of each treatment group. (B) Blood pressure value of each treatment group. (C) Body weight value of each treatment group. (D) Serum potassium level of each treatment group. (E) Blood glucose concentration during intraperitoneal glucose tolerance test (ipGTT) (2 g/kg) of each treatment group. (F) Area under the curve (AUC) of blood glucose concentration during ipGTT of each treatment group. (G) Immunoreactive insulin (IRI) concentration during ipGTT (2 g/kg) of each treatment group. (H) AUC of IRI during ipGTT of each treatment group. * $p < 0.05$. Data are shown as mean \pm SE.

M1 macrophages were accumulated in pancreatic β -cells of Aldosterone group (Figure S1D–F).

To confirm the inflammatory cytokines, which accelerate the accumulation of M1 macrophages, MCP-1 and IL-6 were immunostained in pancreatic islets. Interestingly, although MCP-1 was expressed in the pancreatic β cells of the Aldosterone group (Figure S1A–C), IL-6 was expressed in the α -cells. In addition, although a small number of IL-6-positive pancreatic α -cells were observed in Control islets, IL-6-positive cells were diminished in islets of the Aldosterone group. Upon E+A treatment, the percentage of IL-6-positive α -cells were significantly increased compared with those in the Control or Aldosterone groups (% IL-6-positive α -cells in α -cells: 45.6% \pm 10.2% vs. 7.5% \pm 6.3% vs. 80.7% \pm 5.8% in Control, Aldosterone and E+A groups, respectively; $p < 0.05$) (Figure 2D–F,I). These data indicate

that IL-6 expression in pancreatic α -cells was reduced by the treatment with aldosterone and the treatment of eplerenone restored the IL-6 expression.

In addition, X-box binding protein 1s (XBP1-s) was significantly increased in the pancreas of the Aldosterone group compared with that of the Control or E+A groups. As XBP1-s is a key modulator of unfolded protein response (UPR), these data suggest that endoplasmic reticulum (ER) stress in the pancreas was increased in PA model rodents (Figure S1G).




Figure 2. Histological analysis of pancreatic islets in PA model rodents. (A–C) Masson’s trichrome staining of the islets of each treatment group. (D–F) Double staining of glucagon (red) and IL-6 (green) of the islets of each treatment group. Arrows in F indicate IL-6-positive staining in α -cells. (G) Islet/pancreatic parenchyma area ratio of each group ($n = 10$ slices). (H) Percentages of α -cells area in islet area. (I) Percentages of IL-6-positive α -cells in α -cells. Scale bars in (A–C) = 100 μ m and scale bars in (D–F) = 50 μ m. * $p < 0.05$. Data are shown as mean \pm SE.

3.2. Eplerenone Treatment Increases MR, IL-6 and Active GLP-1 Secretion from α -Cells

A previous report suggests that IL-6 and glucagon are co-expressed in pancreatic α -cell populations during development in murine islets and IL-6 exhibited developmental regulation in the rat pancreas [8]. IL-6 expressed in α -cell may regulate islet/pancreas area ratio, thus we investigate IL-6 and GLP-1 effects and MR/IL-6 axis in α -cells. In addition, previous studies have suggested that IL-6 stimulates active GLP-1 secretion, which is liberated from its precursor proglucagon through processing by the enzyme prohormone convertase (PC) 1/3 [6]. To investigate whether production of IL-6 and active GLP-1 is increased by eplerenone in α -cells, α TC cells were stimulated with vehicle (Control), 10^{-7} M

aldosterone (Aldosterone) or 10^{-7} M aldosterone after pre-treatment with 10^{-5} M eplerenone for 1 h (E+A). Serum and glucocorticoid-regulated kinase 1 (SGK1) mRNA which is activated by aldosterone, was significantly increased in the Aldosterone group and partially restored by E+A (Figure S2A). The MR mRNA level was increased by 1.6-fold in the E+A treatment group compared with the Control group but no changes were observed when the cells were treated with aldosterone alone (Figure 3A). IL-6 mRNA was also increased by 3-fold upon E+A treatment compared with the control and PC1/3 mRNA showed a similar induction pattern to IL-6 (Figure 3B,C).




Figure 3. Alteration of mRNA levels and IL-6 and active GLP-1 concentrations in α TC cells. MR mRNA (A), IL-6 mRNA (B) and PC1/3 mRNA (C) were measured in α TC cells (p5), treated for 24 h with vehicle (Control), 10^{-7} M aldosterone (Aldosterone) or 10^{-7} M aldosterone after 1 h pre-treatment with 10^{-5} M eplerenone (E+A) ($n = 4$, each group). (D) Correlations between the relative quantity of MR mRNA and IL-6 mRNA ($r = 0.99$) or PC1/3 mRNA and IL-6 mRNA ($r = 0.97$) were plotted. IL-6 (E) and active GLP-1 (F) concentrations were determined by ELISA assays in supernatants from treatment groups. Relative mRNA levels of apoptosis-related caspase 3 (G) or anti-apoptosis Bcl2 (H) were measured in each group ($n = 4$, each). * $p < 0.05$. Data are shown as mean \pm SE.

To investigate the effects of eplerenone alone, α TC cells (p8) were stimulated with vehicle (Control), 10^{-5} M eplerenone alone (Eplerenone) or 10^{-7} M aldosterone after pre-treatment with 10^{-5} M eplerenone for 1 h (E+A). IL-6 mRNA was increased by 2.2-fold upon eplerenone treatment compared with the control and PC1/3 mRNA showed a similar induction pattern as IL-6 (Figure S2B,C).

Positive correlations between MR mRNA and IL-6 mRNA as well as PC1/3 mRNA and IL-6 mRNA levels were observed (Figure 3D). Furthermore, while both IL-6 and active GLP-1 concentrations were significantly decreased in the supernatant of the Aldosterone group compared with the Control group ($p = 0.03$), both were significantly increased in the supernatant of the E+A group compared with the Aldosterone group ($p = 0.04$) (Figure 3E,F). We also examined the levels of several apoptosis-related genes. The mRNA level of the pro-apoptotic gene caspase-3 was significantly suppressed and the mRNA level of the apoptosis suppressor gene Bcl-2 was significantly increased in the E+A group compared with both the Control or Aldosterone groups (Figure 3G,H).

As a high aldosterone concentration (10^{-7} M aldosterone (Aldosterone)) may have some effects on the glucocorticoid receptor (GR), 10^{-7} M aldosterone may reduce IL-6 expression due to the GR signal. The experiment was conducted with 10^{-8} M aldosterone to confirm an adequate concentration of aldosterone. There is no difference in IL-6 mRNA expression level between 10^{-7} M aldosterone and 10^{-8} M aldosterone (Figure S2D).

3.3. MR regulates IL-6 expression in α -cells

To investigate the relationship between MR and IL-6 in islet cells, MR expression was modulated in α TC cells using siRNA. When α TC cells were transfected with siRNA targeting MR (siMR), MR mRNA expression was decreased by 34% compared with the control siRNA (CONMR) (Figure 4A). While the control α TC cells showed an increased MR mRNA level by 1.3 fold upon E+A treatment (CONMR E+A) compared with untreated cells, MR mRNA level of the α TC cells transfected with siMR was significantly decreased, by 42%, upon E+A treatment compared with the CONMR E+A group. Furthermore, while IL-6 mRNA level was increased by 3.1 fold in the E+A treated cells transfected with CONMR, this induction of IL-6 mRNA was also blunted by knockdown of MR by siMR (Figure 4B).




Figure 4. MR regulates IL-6 mRNA expression in pancreatic islet cells. MR mRNA (A) or IL-6 mRNA (B) were measured in α TC cells (p9) transfected with control siRNA (CONMR) or siRNA targeting MR (SiMR) and treated by vehicle (Control, C) or eplerenone and aldosterone (E+A) ($n = 4$). MR mRNA (C) and IL-6 mRNA (D) were measured in the 1C3 IKEI pancreatic cells (IKEI cells) ($p = 3$) transfected with empty vector (Control) or human MR-expressing vector (MR+) ($n = 4$). * $p < 0.05$. Data are shown as mean \pm SE.

We also generated a human MR expression vector (MR+) and confirmed significantly increased MR mRNA expression, by 440-fold, upon transfection with the MR+ vector in another α -cell line, IKEI cells (Figure 4C), because IL-6 mRNA expression was not increased in α TC cells transfected with the MR+ vector (Figure S3A). IL-6 mRNA expression was also significantly increased by 8.9-fold in IKEI cells transfected with the MR+ vector compared with controls (Figure 4D).

MR is presumed to differentiate from GR in the process of evolution and the amino acid sequence of its DNA binding domain has 94% homology. Therefore, the DNA binding element of MR overlaps with that of GR. To investigate the relationship between GR and IL-6, we also modulated GR expression in α TC cells using siRNA and human GR expression vector (GR+) (Figure S3B,E). GR (siGR) decreased GR mRNA expression level by 64% compared with the control siRNA (CONGR) (Figure S3B). There was no difference in MR mRNA level and IL-6 mRNA level between siGR Control group and siGR E+A group (Figure S3C,D). GR mRNA expression was increased by 2723-fold upon transfection with the GR+ vector in α -cells (Figure S3E). Overexpression of GR in α -cells significantly decreased IL-6 mRNA expression (Figure S3F).

3.4. Induction of IL-6 Expression by Eplerenone Requires MR Binding Element in the IL-6 Promoter

To determine the mechanism of IL-6 mRNA induction by eplerenone treatment, luciferase assays were performed. A previous report showed that the IL-6 promoter contains a GR binding element (GRE) from -173 to -151 nucleotides upstream of the transcription initiation site [13]. As the amino acid sequence of DNA binding domain of MR and GR has 94% homology, GRE may also act as MRE. We generated luciferase reporter vectors driven by either the wild-type IL-6 promoter containing MRE (IL-6 Luc) or by the mutant promoter in which the MRE was mutated (IL-6 Mutant Luc) (Figure 5A). When α TC cells were transfected with the wild-type IL-6 Luc, luciferase activity was significantly increased by E+A treatment compared with that of either the Control group or the Aldosterone group (Figure 5B). However, when α TC cells were transfected with IL-6 Mutant Luc, E+A failed to induce luciferase activity (Figure 5B).




Figure 5. IL-6 expression in α TC cells upon eplerenone treatment requires MR binding element in the IL-6 gene promoter. (A) The map of the IL-6 gene 5' flanking region is shown on top and the sequences of MRE are shown below (IL-6 Luc). The sequences of mutated MRE used for the experiment are shown below the IL-6 Luc (IL-6 Mutant Luc). The IL-6 promoter DNA fragments (-192 to +51) were ligated into the PGL-3 vector. Black box: MRE, the DNA sequences mutated in the IL-6 Mutant Luc are shown in red characters. White box: exon 1 of IL-6 gene. (B) Luciferase assays in α TC cells (p8) transfected with IL-6 Luc or IL-6 Mutant Luc and treated with control, aldosterone, E+A. * $p < 0.05$. (compared with each group of IL-6 Luc). Data are shown as mean \pm SE.

3.5. Oral Eplerenone Treatment Improves the Impairment of Glucose Homeostasis in Patients with PA

The experiments of PA model rodents and α -cell derived cells suggested that eplerenone administration enhanced active GLP-1 secretion from pancreatic α -cells and improved glucose metabolism. To confirm the active GLP-1 secretion in humans, we measured active GLP-1 concentration in PA patients before and after the eplerenone treatment. The baseline characteristics of the 13 patients with PA included in this study are shown in Figure 6. Glucose tolerance was determined in all cases. The ratio of patients with low potassium (serum potassium level less than 3.5 mEq/L, Merck Manual) was 23%. The frequency of patients with impaired glucose tolerance (IGT) was 77% (Figure 7A). In 13 patients who were treated with the oral MR antagonist eplerenone, active GLP-1 concentration was determined one to three months after the treatment.

Characteristics		Value
	Age	51.5 ± 13.2
	Male	5
Localization	Unilateral	6
	Bilateral	7
	Unidentified	0
	Body Mass Index (kg/m ²)	24.8 ± 4.2
	HbA1c (%)	5.4 ± 0.2
	Serum Potassium Level (mEq/L)	3.7 ± 0.4
	Serum Potassium Level ≤ 3.4 (mEq/L)	3
	Total Cholesterol Level (mg/dL)	194.4 ± 35.1
	Urine free cortisol (µg/day)	42.1 ± 18.7
Glucose Tolerance	Normal Type	3
	IGT Type	10
	DM Type	0

PA: primary aldosteronism; IGT: impaired glucose tolerance; DM: diabetes mellitus.

Figure 6. Baseline Characteristics of PA Patients ($n = 13$).

Homeostasis model assessment for insulin resistance (HOMA-R) was significantly increased after the treatments ($n = 13$; 1.34 ± 0.89 vs. 1.88 ± 0.89 , $p = 0.04$). There were no differences in the insulinogenic index, HbA1c, Σ BG and Σ IRI before and after the treatments ($n = 13$; 0.63 ± 0.43 vs. 0.59 ± 0.38 ; $p = 0.70$, 5.43 ± 0.2 vs. 5.4 ± 0.3 ; $p = 0.60$, 739.6 ± 86.1 vs. 760.9 ± 95.1 ; $p = 0.46$, 266.3 ± 212.8 vs. 272.3 ± 191.5 ; $p = 0.78$). The treatments showed a trend of improved blood glucose concentration at 120 min during 75 g OGTT (148.8 ± 21.1 vs. 142.9 ± 19.1 mg/dL; $p = 0.23$) and resulted in a significant increase of normal glucose tolerance (NGT) response in PA patients ($n = 13$, from 23% to 38%) ($p = 0.0004$, Chi-square test) (Figure 7A,B). Insulin concentration at 60 min during 75 g OGTT showed a trend of increase after the treatments ($n = 13$, 62.7 ± 53.1 vs. 69.3 ± 46.7 µU/mL; $p = 0.30$) (Figure 7C). Interestingly, active GLP-1 concentration at 60 min during OGTT was significantly increased after eplerenone treatment ($n = 13$, 2.74 ± 1.32 vs. 4.56 ± 2.39 pmol/L; $p < 0.05$) (Figure 7D). There were no correlations between GLP-1 and HOMA-R when compared per patient (Figure 7E).

Together, these results indicate that the treatments of PA with eplerenone may increase active GLP-1 secretion, which in turn contributes to improving glucose homeostasis in PA patients.




Figure 7. Glucose homeostasis in PA patients before and after eplerenone treatment ($n = 13$). **(A)** Results of oral glucose tolerance test (OGTT) before and after eplerenone treatment in PA patients (Chi-square test, $** p < 0.01$). NGT: normal glucose tolerance. IGT: impaired glucose tolerance. **(B)** Blood glucose concentration before and after eplerenone treatment during OGTT. **(C)** Immunoreactive insulin (IRI) concentration before and after eplerenone treatment during OGTT. **(D)** Active GLP-1 concentration at 60 min during OGTT before and after eplerenone treatment (paired t-test, $* p < 0.05$). **(E)** Active GLP-1 concentration and HOMA-R per patient. Data are shown as mean \pm SE.

4. Discussion

In this study, we investigated the role of MR on GLP-1 secretion and glucose homeostasis in islets through an in vivo animal model and in vitro cell line experiments and a human clinical study. In the PA model rodents, IL-6 expression was induced in α -cells of pancreatic islets upon eplerenone treatment. This eplerenone-dependent IL-6 induction requires specific binding elements for MR (MREs) in the IL-6 gene promoter. We found that the oral eplerenone treatment increased active GLP-1 secretion and reduced the number of patients with IGT. The MR-dependent IL-6 induction contributes to increase active GLP-1 levels through the induction of PC1/3 and thus may protect islets from metabolic insults (Figure 8).

To investigate how glucose homeostasis is regulated by MR in pancreatic islets cells, we examined ipGTT in the PA model rodents. We found that glucose AUC was increased and IRI AUC was decreased during ipGTT in the Aldosterone group of rodents (Figure 1). As the result suggested that the eplerenone treatment somehow improved insulin secretion, we carried out histological analysis of pancreatic islets in the PA rodent model to further determine the detailed mechanism of increased insulin secretion by eplerenone.

In histological examination, MCP-1 was expressed in pancreatic β -cells and M1 macrophages were accumulated in the Aldosterone group. Inflammation in β -cells by aldosterone may cause more substantial effects in PA model rodents. We also found that the pancreatic islet area ratio was reduced in the Aldosterone group and was restored by E+A treatment, in parallel with the induction of IL-6

in α -cells of pancreatic islets (Figure 2). Recent reports showed that IL-6 stimulates GLP-1 secretion from α -cells by the activation of PC1/3 to convert from precursor proglucagon into mature GLP-1 [6]. Indeed, IL-6 as well as active GLP-1 induction were observed by E+A in our experiments (Figure 3).




Figure 8. Proposed mechanism for MR in pancreatic islets. MR signal exerts a protective function in islets through IL-6 induction, which promotes active GLP1 secretion through PC1/3 activation. (1) MR induced from eplerenone, alone or in an eplerenone-MR complex, may bind to MRE in P2 in α -cells and promote MR expression. (2) MR and/or an eplerenone-MR complex may bind to the MRE in the IL-6 promoter to drive IL-6 expression. (3) IL-6 activation leads to increased PC1/3 mRNA levels and (4) induced PC1/3 may cleave proglucagon into GLP-1 in α -cells, resulting in elevated plasma levels of GLP-1. (5) Autocrine signaling of GLP-1 in α -cells may increase the expression of Bcl-2 mRNA and reduce the levels of caspase-3 mRNA, leading to protection of α -cells from apoptosis. (6) Paracrine signaling of GLP-1 in β -cells may increase the expression of Pdx-1 mRNA and reduce the levels of caspase-3 mRNA, thus protecting β -cells from endoplasmic reticulum stress and apoptosis.

In addition, we found that endoplasmic reticulum (ER) stress in the pancreas was increased in PA model rodents and was restored by E+A treatment. Recent reports have suggested the importance of α -cell-derived GLP-1 for glucose homeostasis during aging and metabolic stress [14]. ER stress in pancreatic islets was reported as a mediator of nitric oxide-induced apoptosis [15] and an age-dependent modifier of islet survival and function [16]. Because ER stress could be suppressed by GLP-1 [17], treatment with eplerenone in PA model rodents may protect pancreatic β -cells through reduced ER stress by increased secretion of active GLP-1 from α -cells (Figure 8, #6).

To confirm the induction of IL-6 and increased secretion of GLP-1 by eplerenone treatment in α -cells, we performed experiments using α -cell-derived cell lines. First, we found that MR mRNA

expression was significantly increased in α TC cells by E+A treatment. Although the mechanism of eplerenone-induced MR upregulation was not elucidated in this study, we speculate that an eplerenone-MR complex may bind to MRE in P2 promoter of the MR gene in α -cells and promote MR expression (Figure 8, #1). A previous study reported the presence of two functional promoters in the human MR gene—referred to as P1 and P2—in the 5'-flanking regions [18]. Although aldosterone was shown to stimulate both P1 and P2 activity in murine embryonic stem cell lines, MR knock down inhibits aldosterone-induced P2 promoter activity [19], indicating that P2 could contain a functional MRE. Whether an eplerenone-MR complex binds to the MRE of P2 in α -cells, remains to be elucidated. The functional association and characterization of MR and the MRE in the MR gene should be investigated in future studies.

Second, we confirmed that MR induces IL-6 by binding with IL-6 promoter (Figure 8, #2). Our in vitro studies also revealed that the expression level of MR and IL-6 mRNA showed a similar pattern and correlated positively with each other. The discrepancy observed between increased IL-6 and GLP-1 gene expression and reduced release in supernatants may be due to the fact that the mechanisms regulating the proinflammatory cytokines, without signal peptide, are not fully understood. Previous reports revealed that microvesicle shedding is a major secretory pathway for rapid IL-1 β release from activated monocytes and may represent a more general mechanism of the secretion of similar leaderless secretory proteins [20]. In our study, IL-10 mRNA expression was significantly increased in the Aldosterone group compared with the control and the E+A group in α TC cells (Figure S4). IL-10 altered the number of autophagosome (microvesicle) in myocytes treated with Angiotensin II [21]. In addition, previous reports suggest that the activation of IL-10 receptors leads to the inhibition of IL-6 release [22,23]. Thus IL-6 and GLP-1 release in the supernatants may be decreased in the Aldosterone group. More detailed mechanisms should be clarified in future. Notably, a previous report showed that the IL-6 promoter contains a GRE [13]. These data suggest that an eplerenone-MR complex may bind to the GRE (= MRE) in the IL-6 promoter.

We further investigated the mechanism of MR regulation of IL-6 expression in α -cells. The eplerenone-stimulated induction of IL-6 appeared to be MR expression dependent as shown in our siRNA data. In addition, overexpression of MR alone increased the level of IL-6 mRNA, indicating that unbound MR may directly associate with MRE to activate IL-6 expression, because these experiments were performed in a glucocorticoid- and mineralocorticoid-free environment. Indeed, a previous report showed that MR overexpression in ES cell-derived cardiomyocytes increased beating frequency without aldosterone, suggesting that cardiac MR is at least partially activated in a ligand-independent manner [24]. Furthermore, we performed luciferase assays using IL-6 gene promoter with or without the potential MRE in α -cells. Interestingly, E+A but not aldosterone alone activated the IL-6 promoter, suggesting that the eplerenone-MR complex or MR alone may drive IL-6 expression through the MRE. Although the GR-binding site of the IL-6 promoter between -173 to -145 lack discernible inverted repeats, sequences show similarity with a negative GRE sequence [13]. GRs can remain as monomers and interact with transcription factors such as activating protein-1 (AP-1) or nuclear factor- κ B [25]. Monomer MRs was increased when the α -cells were treated with eplerenone. The monomer MRs may be able to interact with MRE in the absence of ligand. However, IL-6 mRNA expression did not increase in α TC cells transfected with human MR-expressing vector (MR+). This suggests that human MR may not bind with the MRE of the IL-6 promoter in murine α -cells. In addition, GR did not mediate the increase of IL-6 mRNA expression in α -cells (Figure S3A–F).

Third, IL-6 may activate PC1/3 promoter (Figure 8, #3). We confirmed that IL-6 and PC1/3 mRNA levels correlated with each other in α -cells. IL-6 secretion and active GLP-1 secretion from α -cells are both significantly increased upon E+A treatment. Indeed, a previous report showed that IL-6 treatment increased the expression of GLP-1 and PC1/3 mRNA in human α -cells [6]. In addition, a recent study showed that IL-6 significantly increased both PC1 protein and mRNA in mouse corticotroph AtT-20 cells through a Janus kinase (JAK)-signal transducers and activator of transcription (STAT)-related

pathway, which is involved in the transcriptional regulation of PC1 gene expression through a PC1 promoter regulatory element [26].

Fourth, PC1/3 may induce active GLP-1 secretion (Figure 8, #4). We verified that E+A treatment significantly increased GLP-1 secretion compared with aldosterone treatment in the α -cell line. A previous report showed that induced PC1/3 cleaves proglucagon into GLP-1 in α -cells, resulting in elevated plasma levels of GLP-1 [27].

Finally, active GLP-1 may protect islet cells from apoptosis (Figure 8, #5 and #6). To investigate the mechanism of cell protection in pancreatic islets, we measured apoptosis-related genes in α -cells. Caspase-3 mRNA significantly decreased, and Bcl-2 mRNA significantly increased, upon E+A treatment, indicating that treatment with eplerenone may protect α -cells from apoptosis. Previous reports have identified a preventative effect of eplerenone from apoptosis in glomerular cells and cardiomyocytes [28,29]. In addition, one report suggested that GLP-1 treatment increased the expression of Bcl-2 and reduced the levels of caspase-3 in retinal cells in type 2 diabetic rats through the GLP-1 receptor-extracellular signal regulated kinase 1/2-histone deacetylase 6 (GLP-1R-ERK 1/2-HDAC 6) signaling pathway [30]. Indeed, a recent report detected GLP-1R in α -cells and chronic exposure to GLP-1 increased GLP-1 synthesis from α TC cells [31]. Thus, eplerenone treatment may protect α -cells from apoptosis through autocrine signaling of GLP-1.

We confirmed that pancreas/duodenum homeobox 1 (Pdx-1) mRNA expression was significantly decreased and caspase-3 mRNA expression was significantly increased in MIN6 cells treated with aldosterone compared with the control and E+A groups (Figure S5A,B). We previously showed that the GLP-1 agonist Exendin-4 upregulated Pdx-1 in regenerating α -cells [32]. In addition, several studies have suggested that increased activation of GLP-1R in α -cells is beneficial for insulin secretion, proliferation and anti-apoptosis activities of the β -cell [17,33–35]. Together these findings indicate that eplerenone treatment increases GLP-1 secretion in α -cells and the GLP-1 could protect β -cells from apoptotic signals (Figure 8, #6).

Considering that glucocorticoids bind not only the glucocorticoid receptor but also MR with comparable affinity to aldosterone, and glucocorticoids have a 102–103-fold higher blood concentration compared with aldosterone, glucocorticoids have to be converted to the deactivated form by 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2) to retain the specific action of aldosterone by MR [10]. Our data showed that 11 β -HSD2 mRNA was significantly increased in cells treated with eplerenone (Figure S6), suggesting that islets are mainly regulated by MR signals but not glucocorticoid receptor signals. A recent report revealed that 11 β -HSD1 mRNA is essentially undetectable in both α -cells and cells in purified human islets [36]. In addition, 11 β -HSD2 mRNA was detectable at much lower levels in pancreatic islets and the MIN6 cell line than that in kidney [4]. However, as a high fat diet induces a modest elevation of 11 β -HSD1 in the islets of rodents [37], the expression level of 11 β -HSD may be regulated by nutritional environment of islets. Since only few reports have examined 11 β -HSD2 in islet cells, more detailed mechanisms must be investigated in future studies.

To explain the mechanism of impaired glucose homeostasis in human PA patients, impaired insulin secretion due to hypokalemia was initially described [38] and another study discussed insulin resistance in PA subjects [39]. Although 77% of PA subjects in this study showed impairment of glucose tolerance, the frequency of patients with hypokalemia was only 23%. This suggests that low potassium levels may only have a small influence on glucose intolerance in PA. In addition, as homeostasis model assessment insulin resistance (HOMA-R) was significantly increased after treatment of PA patients with oral eplerenone administration, insulin resistance may not be the major pathophysiology of glucose intolerance in PA patients. In a previous report, active GLP-1 at 60 min after glucose load in Japanese non-obese healthy subjects was around 8 pmol/L [40]. In our data, the active GLP-1 secretion at 60 min after glucose load in PA patients (2.7 pmol/L) was much lower, suggesting the impaired GLP-1 secretion in PA patients. Furthermore, active GLP-1 concentration was significantly increased after eplerenone treatment in this study. In addition, active GLP-1 concentration was significantly decreased in the supernatant of α TC cells which were treated with aldosterone, thus aldosterone/MR-mediated decrease

of GLP-1 secretion may be one of the main contributors to the impairment of glucose homeostasis in PA patients. Recent studies have shown that GLP-1 concentration is lower in type 2 diabetic patients than that in healthy subjects [41,42]. Salt intake affects the serum GLP-1 level in normotensive salt-sensitive subjects [43]. In addition, MR blockade in healthy adults tended to improve postprandial glucose concentration and insulin secretion [44]. Indeed, normalization of GLP-1 secretion by MR blockade suppressed prolonged hyperglycemia. Normal GLP-1 secretion may protect islet cells in the long term. This study is the first to elucidate further details of the relationship between MR and glucose homeostasis by measuring active GLP-1 response to oral glucose load before and after oral eplerenone treatment in PA patients.

5. Conclusions

In summary, we have identified a novel mechanism by which the MR signal exerts a protective function in rodent and human islets through the engagement of IL-6 induction, PC 1/3 activation and the active GLP-1 secretion pathway (Figure 8). This illustrates the toxicity of aldosterone excess in the pathogenesis of glucose intolerance in PA. Eplerenone may have a potential benefit for diabetic therapy with its effect of increasing GLP-1 secretion in α -cells. Understanding this signaling in more detail may provide therapeutic alternatives for the treatment of diabetes.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2077-0383/8/5/674/s1>, Figure S1: Inflammation and endoplasmic reticulum stress in PA model rodents, Figure S2: Alteration of mRNA levels in α TC cells, Figure S3: Relationship between MR, GR and IL-6 mRNA expression in pancreatic islet cells, Figure S4: Evaluation of IL-10 mRNA levels in α TC cells. Figure S5: Evaluation of mRNA levels in MIN6 cells, Figure S6: Evaluation of 11 β -HSD2 mRNA levels in MIN6 and α TC cells, Table S1: List of qPCR primers, Table S2: List of siRNA sequences, Table S3: List of qPCR primers and sense sequence for mutated MRE.

Author Contributions: Conceptualization, R.G.; methodology, R.G.; software, R.G.; validation, K.O., S.K., N.M., T.W., M.S. (Masaji Sakaguchi), M.S. (Miki Sato), M.I., J.K., H.M., T.M. and S.S.; formal analysis, R.G.; investigation, K.O., S.K., N.M., T.W., M.S. (Masaji Sakaguchi), M.S. (Miki Sato), M.I., J.K., H.M., T.M. and S.S.; resources, R.G.; data curation, R.G., T.K. and E.A.; writing—original draft preparation, R.G., T.K. and E.A.; writing—review and editing, R.G., T.K. and E.A.; visualization, R.G., T.K. and E.A.; supervision, T.K. and E.A.; project administration, R.G., T.K. and E.A.; funding acquisition, R.G., T.K. and E.A.

Funding: This research was funded by part of JSPS KAKENHI Grant Number 17K09837.

Acknowledgments: The authors are grateful to the patients and also wish to thank the staff of the Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University for their assistance with the study. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

References

1. Elliottz, W.J.; Meyer, P.M. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. *Lancet* **2007**, *369*, 201–207. [[CrossRef](#)]
2. Luther, J.M.; Brown, N.J. The renin-angiotensin-aldosterone system and glucose homeostasis. *Trends Pharmacol. Sci.* **2011**, *32*, 734–739. [[CrossRef](#)] [[PubMed](#)]
3. Luther, J.M. Effects of aldosterone on insulin sensitivity and secretion. *Steroids* **2014**, *91*, 54–60. [[CrossRef](#)] [[PubMed](#)]
4. Luther, J.M.; Luo, P.; Kreger, M.T.; Brissova, M.; Dai, C.; Whitfield, T.T.; Kim, H.S.; Wasserman, D.H.; Powers, A.C.; Brown, N.J. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. *Diabetologia* **2011**, *54*, 2152–2163. [[CrossRef](#)] [[PubMed](#)]
5. Koizumi, M.; Yada, T. Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca^{2+} responses to glucose in pancreatic beta-cells. *J. Endocrinol.* **2008**, *197*, 221–229. [[CrossRef](#)] [[PubMed](#)]
6. Ellingsgaard, H.; Hauselmann, I.; Schuler, B.; Habib, A.M.; Baggio, L.L.; Meier, D.T.; Eppler, E.; Bouzakri, K.; Wueest, S.; Muller, Y.D.; et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from I cells and alpha cells. *Nat. Med.* **2011**, *17*, 1481–1489. [[CrossRef](#)] [[PubMed](#)]

7. Baggio, L.L.; Drucker, D.J. Biology of incretins: Glp-1 and GIP. *Gastroenterology* **2007**, *132*, 2131–2157. [[CrossRef](#)]
8. Fernandez-Millan, E.; de Toro-Martin, J.; Lizarraga-Mollinedo, E.; Escriva, F.; Alvarez, C. Role of endogenous il-6 in the neonatal expansion and functionality of wistar rat pancreatic alpha cells. *Diabetologia* **2013**, *56*, 1098–1107. [[CrossRef](#)] [[PubMed](#)]
9. Blasi, E.R.; Rocha, R.; Rudolph, A.E.; Blomme, E.A.; Polly, M.L.; McMahon, E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. *Kidney Int.* **2003**, *63*, 1791–1800. [[CrossRef](#)]
10. Kiyosue, A.; Nagata, D.; Myojo, M.; Sato, T.; Takahashi, M.; Satonaka, H.; Nagai, R.; Hirata, Y. Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. *Hypertens. Res. Off. J. Jpn. Soc. Hypertens.* **2011**, *34*, 1283–1287. [[CrossRef](#)] [[PubMed](#)]
11. Miller, C.A., 3rd; Tan, X.; Wilson, M.; Bhattacharyya, S.; Ludwig, S. Single plasmids expressing human steroid hormone receptors and a reporter gene for use in yeast signaling assays. *Plasmid* **2010**, *63*, 73–78. [[CrossRef](#)]
12. Carey, K.L.; Richards, S.A.; Lounsbury, K.M.; Macara, I.G. Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the ran/tc4 gtpase mediates an essential function independent of nuclear protein import. *J. Cell Biol.* **1996**, *133*, 985–996. [[CrossRef](#)]
13. Ray, A.; LaForge, K.S.; Sehgal, P.B. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, tata box and RNA start site (INR motif) occlusion. *Mol. Cell. Biol.* **1990**, *10*, 5736–5746. [[CrossRef](#)] [[PubMed](#)]
14. Traub, S.; Meier, D.T.; Schulze, F.; Dror, E.; Nordmann, T.M.; Goetz, N.; Koch, N.; Dalmás, E.; Stawiski, M.; Makshana, V.; et al. Pancreatic alpha cell-derived glucagon-related peptides are required for beta cell adaptation and glucose homeostasis. *Cell Rep.* **2017**, *18*, 3192–3203. [[CrossRef](#)]
15. Oyadomari, S.; Takeda, K.; Takiguchi, M.; Gotoh, T.; Matsumoto, M.; Wada, I.; Akira, S.; Araki, E.; Mori, M. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 10845–10850. [[CrossRef](#)]
16. Mihailidou, C.; Chatzistamou, I.; Papavassiliou, A.G.; Kiaris, H. Modulation of pancreatic islets' function and survival during aging involves the differential regulation of endoplasmic reticulum stress by p21 and chop. *Antioxid. Redox Signal.* **2017**, *27*, 185–200. [[CrossRef](#)]
17. Yusta, B.; Baggio, L.L.; Estall, J.L.; Koehler, J.A.; Holland, D.P.; Li, H.; Pipeleers, D.; Ling, Z.; Drucker, D.J. Glp-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. *Cell Metab.* **2006**, *4*, 391–406. [[CrossRef](#)]
18. Zennaro, M.C.; Le Menuet, D.; Lombes, M. Characterization of the human mineralocorticoid receptor gene. *Mol. Endocrinol.* **1996**, *10*, 1549–1560. [[PubMed](#)]
19. Munier, M.; Meduri, G.; Viengchareun, S.; Leclerc, P.; Le Menuet, D.; Lombes, M. Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells. *Endocrinology* **2010**, *151*, 2244–2254. [[CrossRef](#)] [[PubMed](#)]
20. MacKenzie, A.; Wilson, H.L.; Kiss-Toth, E.; Dower, S.K.; North, R.A.; Surprenant, A. Rapid secretion of interleukin-1beta by microvesicle shedding. *Immunity* **2001**, *15*, 825–835. [[CrossRef](#)]
21. Samanta, A.; Dawn, B. Il-10 for cardiac autophagy modulation: New direction in the pursuit of perfection. *J. Mol. Cell. Cardiol.* **2016**, *91*, 204–206. [[CrossRef](#)]
22. Sabat, R.; Grutz, G.; Warszawska, K.; Kirsch, S.; Witte, E.; Wolk, K.; Geginat, J. Biology of interleukin-10. *Cytokine Growth Factor Rev.* **2010**, *21*, 331–344. [[CrossRef](#)]
23. Hempel, L.; Korholz, D.; Bonig, H.; Schneider, M.; Klein-Vehne, A.; Packeisen, J.; Mauz-Korholz, C.; Burdach, S. Interleukin-10 directly inhibits the interleukin-6 production in t-cells. *Scand. J. Immunol.* **1995**, *41*, 462–466. [[CrossRef](#)]
24. Le Menuet, D.; Munier, M.; Meduri, G.; Viengchareun, S.; Lombes, M. Mineralocorticoid receptor overexpression in embryonic stem cell-derived cardiomyocytes increases their beating frequency. *Cardiovasc. Res.* **2010**, *87*, 467–475. [[CrossRef](#)] [[PubMed](#)]
25. Inaba, H.; Pui, C.H. Glucocorticoid use in acute lymphoblastic leukaemia. *Lancet Oncol.* **2010**, *11*, 1096–1106. [[CrossRef](#)]
26. Li, Q.L.; Jansen, E.; Friedman, T.C. Regulation of prohormone convertase 1 (pc1) by gp130-related cytokines. *Mol. Cell. Endocrinol.* **1999**, *158*, 143–152. [[CrossRef](#)]
27. Habener, J.F.; Stanojevic, V. Alpha cells come of age. *Trends Endocrinol. Metab.* **2013**, *24*, 153–163. [[CrossRef](#)] [[PubMed](#)]

28. Liang, W.; Chen, C.; Shi, J.; Ren, Z.; Hu, F.; van Goor, H.; Singhal, P.C.; Ding, G. Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. *Nephrol. Dial. Transplant.* **2011**, *26*, 789–799. [[CrossRef](#)]
29. Ramirez, E.; Klett-Mingo, M.; Ares-Carrasco, S.; Picatoste, B.; Ferrarini, A.; Ruperez, F.J.; Caro-Vadillo, A.; Barbas, C.; Egido, J.; Tunon, J.; et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-ii diabetes. *Cardiovasc. Diabetol.* **2013**, *12*, 172. [[CrossRef](#)] [[PubMed](#)]
30. Cai, X.; Li, J.; Wang, M.; She, M.; Tang, Y.; Li, J.; Li, H.; Hui, H. Glp-1 treatment improves diabetic retinopathy by alleviating autophagy through glp-1r-erk1/2-hdac6 signaling pathway. *Int. J. Med. Sci.* **2017**, *14*, 1203–1212. [[CrossRef](#)]
31. Piro, S.; Mascali, L.G.; Urbano, F.; Filippello, A.; Malaguarnera, R.; Calanna, S.; Rabuazzo, A.M.; Purrello, F. Chronic exposure to glp-1 increases glp-1 synthesis and release in a pancreatic alpha cell line (alpha-tc1): Evidence of a direct effect of glp-1 on pancreatic alpha cells. *PLoS ONE* **2014**, *9*, e90093. [[CrossRef](#)]
32. Kodama, S.; Toyonaga, T.; Kondo, T.; Matsumoto, K.; Tsuruzoe, K.; Kawashima, J.; Goto, H.; Kume, K.; Kume, S.; Sakakida, M.; et al. Enhanced expression of pdx-1 and ngn3 by exendin-4 during beta cell regeneration in stz-treated mice. *Biochem. Biophys. Res. Commun.* **2005**, *327*, 1170–1178. [[CrossRef](#)] [[PubMed](#)]
33. Buteau, J. Glp-1 receptor signaling: Effects on pancreatic beta-cell proliferation and survival. *Diabetes Metab.* **2008**, *34* (Suppl. 2), S73–S77. [[CrossRef](#)]
34. Cornu, M.; Yang, J.Y.; Jaccard, E.; Poussin, C.; Widmann, C.; Thorens, B. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an igf-2/igf-1 receptor autocrine loop. *Diabetes* **2009**, *58*, 1816–1825. [[CrossRef](#)]
35. Liu, J.; Yin, F.; Xiao, H.; Guo, L.; Gao, X. Glucagon-like peptide 1 receptor plays an essential role in geniposide attenuating lipotoxicity-induced beta-cell apoptosis. *Toxicol. In Vitro* **2012**, *26*, 1093–1097. [[CrossRef](#)] [[PubMed](#)]
36. Pullen, T.J.; Huising, M.O.; Rutter, G.A. Analysis of purified pancreatic islet beta and alpha cell transcriptomes reveals 11beta-hydroxysteroid dehydrogenase (hsd11b1) as a novel disallowed gene. *Front. Genet.* **2017**, *8*, 41. [[CrossRef](#)]
37. Turban, S.; Liu, X.; Ramage, L.; Webster, S.P.; Walker, B.R.; Dunbar, D.R.; Mullins, J.J.; Seckl, J.R.; Morton, N.M. Optimal elevation of beta-cell 11beta-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced beta-cell failure. *Diabetes* **2012**, *61*, 642–652. [[CrossRef](#)]
38. Shimamoto, K.; Shiiki, M.; Ise, T.; Miyazaki, Y.; Higashiura, K.; Fukuoka, M.; Hirata, A.; Masuda, A.; Nakagawa, M.; Iimura, O. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? *J. Hum. Hypertens.* **1994**, *8*, 755–759. [[PubMed](#)]
39. Watanabe, D.; Yatabe, M.; Ichihara, A. Evaluation of insulin sensitivity and secretion in primary aldosteronism. *Clin. Exp. Hypertens.* **2016**, *38*, 613–617. [[CrossRef](#)]
40. Nagai, E.; Katsuno, T.; Miyagawa, J.; Konishi, K.; Miuchi, M.; Ochi, F.; Kusunoki, Y.; Tokuda, M.; Murai, K.; Hamaguchi, T.; et al. Incretin responses to oral glucose load in japanese non-obese healthy subjects. *Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord.* **2011**, *2*, 20–28. [[CrossRef](#)]
41. Muscelli, E.; Mari, A.; Casolaro, A.; Camastra, S.; Seghieri, G.; Gastaldelli, A.; Holst, J.J.; Ferrannini, E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. *Diabetes* **2008**, *57*, 1340–1348. [[CrossRef](#)] [[PubMed](#)]
42. Lastya, A.; Saraswati, M.R.; Suastika, K. The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. *BMC Res. Notes* **2014**, *7*, 849. [[CrossRef](#)] [[PubMed](#)]
43. Zheng, W.L.; Chu, C.; Lv, Y.B.; Wang, Y.; Hu, J.W.; Ma, Q.; Yan, Y.; Cao, Y.M.; Dang, X.L.; Wang, K.K.; et al. Effect of salt intake on serum glucagon-like peptide-1 levels in normotensive salt-sensitive subjects. *Kidney Blood Press. Res.* **2017**, *42*, 728–737. [[CrossRef](#)] [[PubMed](#)]
44. Krug, A.W.; Stelzner, L.; Rao, A.D.; Lichtman, A.H.; Williams, G.H.; Adler, G.K. Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. *Metab. Clin. Exp.* **2013**, *62*, 386–391. [[CrossRef](#)] [[PubMed](#)]



Table S1: List of qPCR primers

Gene	species	Forward primers	Reverse primers
GAPDH	mouse	TCACCACCATGGAGAAGGC	CCTAAGCAGTTGGTGGTGCA
GAPDH	human	CATGTTCCAATATGATTCCACC	CTCCATGGTGGTGAAGACGC
Caspase-3	mouse	TCTGACTGGAAAGCCGAAACTC	TTCCACTGTCTGTCTCAATAC
Bcl-2	mouse	GGCTACGAGTGGGATACTGGAG	AGGCTGGAAGGAGAAGATGC
MR	mouse	GCGTTCTTCTTTGGACCTG	GCAAATCCCAGACCGACTA
MR	human	GAAAGACGGTGGGGTCAAG	TGCTGAAGGCAAGGGAGTAG
GR	mouse	GGGCGCCAAGTGATTGCCGCAGT	CCAACCCAGGGCAAATGCCATGA
GR	human	GGGCGGCAAGTGATTGCAGCAGT	CCACCCCAGAGCAAATGCCATAA
IL-6	mouse	AGTTGCCTTCTTGGGACTGA	CTGTGAAGTCTCCTCTCCGG
IL-6	human	CCTAGAGTACCTCCAGAACAG	CTTCGTCAGCAGGCTGGCA
PC1/3	mouse	CATCTTTGTCTGGGCTTCAGG	GCTTGTTATTGCTGGTCTGTG
Pdx-1	mouse	CTGCCACCATGAACAGTGAG	GATCCCAGCGAGCTTGTAAG
SGK1	mouse	TTGGGGCTGTCTGTATGAG	GGTGCCTTGCCGAGTTTG

Table S2: List of siRNA sequences.

	sequence
siMR	CCCGCUCAACAUGCCGUCUUCAGUA
siGR	GCCAUUUCUGUUCAUGGCGUGAGUA
CONMR	CCCAGUACACGUUGCUUCACGCGUA
CONGR	GCCUCUUCAUCGGUAGUGCAUAGUA

siMR: siRNA targeting MR; siGR: siRNA targeting GR; CONMR: negative control siRNA (MR sense sequence); CONGR: negative control siRNA (GR sense sequence).

Table S3: List of qPCR primers and sense sequence for mutated MRE.

Gene	Forward primer	Reverse primer
IL-6 promoter	GTGGTACCCCCTAGTTGTGTCTTGC	CTGGAGGGGAGATAGAGCTTC

	hybridized oligonucleotides sequence
mutated MRE	GTGGTACCCCCTAGTTGTGTCTTGCCATTTTAAATTTTTTTTCATTTTTTAATTTTAATAAGGTTT CCAATCAGCCCCACCCGCTCTGGCCCCACCCTCACCTCCAACAAAGATTTATCAAATGTGGG ATTTTCCCATGAGTCTCAATATTAGAGTCTCAACCCCAATAAATATAGGACTGGAGATGTCTG AGGCTCATTCTGCCCTCGAGCCCACCGGAACGAAAGAGAAGCTCTATCTCCCCTCCAG

Figure S1







Figure S2


A



B



C



D




Figure S3




Figure S4





Figure S5

A



B




Figure S6

